Coriolis Pharma, a globally operating contract research and development organization (CRDO) and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, ATMP´s and vaccines, is expanding its current headquarters to form a new campus as the next step in its growth strategy.
Located in the heart of the biotech cluster Martinsried in Munich, Germany, the new Coriolis Campus will double the overall capacities to 14000 sqm. It will include two new buildings, the current headquarters, and two additional locations. The new campus with interconnected buildings will provide additional lab and office space, thus giving the company sustainable growth opportunities. The first building will be operational in early 2024, while the completion of the entire Coriolis Campus is planned for 2025.
“Coriolis Pharma is investing strongly in creating new attractive jobs in Martinsried,“ said Silvia Steyrer-Gruber, CEO of Coriolis Pharma. “The Coriolis Campus will be designed for our employees, offering new workspaces, meeting zones, a conference centre and an employee restaurant. We formulate innovation by working together.”
“We will plan and develop all facilities to be energy-efficient and sustainable,” said Dr Michael Wiggenhorn, Member of Board of Directors. “We will focus on energy by photovoltaics and geothermal sources as part of our concept.”
In the first construction phase, a modern lab infrastructure, including multipurpose facilities and office spaces will be established. In a second construction phase, a new facility with an employee restaurant and meeting places will be built.